Safety and efficacy of TPO‐RAs and anti‐CD20 in ITP have been demonstrated in many single‐arm clinical trials,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 with some studies highlighting the potential for treatment‐free remission following TPO‐RA discontinuation;32, 33, 34, 35 and similar effects seen with anti‐CD20.36, 37, 38, 39. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.